Merck & Co. Stories
J&J to cut jobs in restructuring
Johnson & Johnson said on Tuesday it planned to eliminate 3 percent to 4 percent of its global work force of about 120,500 people as part of a plan to improve its cost structure. The cost-cutting plan is expected to generate pretax cost savings of $1.3 billion to $1.6 billion in 2008, the diversified health care company said.
Schering-Plough profit doubles, beating forecasts
Schering-Plough Corp. on Monday said quarterly earnings more than doubled on growing demand for its Zetia and Vytorin cholesterol drugs and its treatments for arthritis and allergies.
Merck Vioxx heart risks began sooner: WSJ
Heart risks associated with Merck & Co.'s painkiller Vioxx began much sooner than the company has claimed, The Wall Street Journal Online reported on Tuesday, citing a new study.
Intercell wins $363 mln Novartis deal, shares jump
Austrian biotech firm Intercell won a deal to sell shares and rights to its vaccine technology to drugmaker Novartis for 270 million euros ($363 million), pushing its stock to all-time highs on Monday.
Merck Loses Vioxx Case
A jury in a U.S. federal court found that pharmaceuticals company Merck & co. was responsible for the death of a man who took the company's Vioxx painkiller drug.
FTSE soars as oil dips, Vodafone up
UK stocks closed at their highest level in nearly two weeks on Monday as numbers from Vodafone boosted investor confidence at the start of a busy earnings week and concerns over the conflict in Lebanon eased slightly.
Schering-Plough Exceeds Wall Street Expectations
Drug maker Schering-Ploughdrugs, announced on Monday that its 2006 second quarter earnings surpassed Wall Street expectations due to a surge in the sales of key drugs.
Schering-Plough profit eclipses expectations
Schering-Plough Corp. on Monday reported quarterly earnings far higher than Wall Street expected, fueled by growing demand for its drugs against cholesterol, arthritis, allergies and hepatitis C.
Pfizer Posts 30 Pct. Profit Decrease in 2Q
Pfizer, the world's largest drug maker, posted a 30 percent decrease in net income for the second quarter on Thursday as it faces strong challenges from generic competitors in the market after losing its patent rights over two of the most profitable drug for the firm.